Q-omics provides the consensus-scored KRT8P12 profile across patient tissues and cancer cell-line models. KRT8P12 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, KRT8P12 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, KRT8P12 RNA expression shows 18,622 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight COAD, HNSC, and ACC as cancer lineages where KRT8P12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT8P12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT8P12 survival associations across molecular data types. KRT8P12 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT8P12 RNA expression–survival associations across cancer types. High KRT8P12 expression shows unfavorable associations in COAD, KIRC, ACC, STAD, MESO and BRCA. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for KRT8P12 RNA expression.
This table summarizes KRT8P12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for KRT8P12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT8P12 shows higher tumor expression in HNSC, KIRC, KIRP, STAD, COAD and LIHC. The HNSC box plot shows higher KRT8P12 RNA expression in tumor versus normal tissue (log2 FC = +1.221, t-test p < 0.001).
This table shows molecular features associated with KRT8P12 in patient tissues and cancer cell lines. In patient samples, KRT8P12 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, KRT8P12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in NCI60_ALL.
